Association of a functional polymorphism in neuropeptide y with antipsychotic-induced weight gain in schizophrenia patients

Journal of Clinical Psychopharmacology

Volumn 33, Issue 1, 2013, Pages 11-17

  Tiwari, Arun K ^a   Brandl, Eva J ^a   Weber, Caroline ^b   Likhodi, Olga ^a   Zai, Clement C ^a   Hahn, Margaret K ^a   Lieberman, Jeffrey A ^c   Meltzer, Herbert Y ^d   Kennedy, James L ^a   Müller, Daniel J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Oberhavel Kliniken GmbH   (Germany)

^c Columbia University ^*  (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

association; clozapine; NPY; rs16147; weight gain

Indexed keywords

CANNABINOID 1 RECEPTOR; CLOZAPINE; NEUROPEPTIDE Y; OLANZAPINE;

ADULT; ALLELE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADULT; AFRICAN AMERICANS; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHI-SQUARE DISTRIBUTION; CLOZAPINE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENOTYPE; GERMANY; HUMANS; MALE; MIDDLE AGED; NEUROPEPTIDE Y; NEW YORK; OHIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB1; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA; WEIGHT GAIN; YOUNG ADULT;

EID: 84873096725     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31827d145a     Document Type: Article

References (62)

1. Crisp AH, Gelder MG, Rix S, et al. Stigmatisation of people with mental illnesses. Br J Psychiatry. 2000;177:4-7.
2. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
3. Gebhardt S, Theisen FM, Haberhausen M, et al. Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther. 2010;35:207-211.
4. Theisen FM, Gebhardt S, Haberhausen M, et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatr Genet. 2005;15:285-289.
5. Wehmeier PM, Gebhardt S, Schmidtke J, et al. Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry Res. 2005;133:273-276.
6. Lett TA, Wallace TJ, Chowdhury NI, et al. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry. 2012;17:242-266.
7. Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther. 2010;127:210-251.
8. Kluge M, Schuld A, Himmerich H, et al. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol. 2007;27: 662-666.
9. Blouin M, Tremblay A, Jalbert ME, et al. Adiposity and eating behaviors in patients under second generation antipsychotics. Obesity (Silver Spring). 2008;16:1780-1787.
10. Case M, Stauffer VL, Ascher-Svanum H, et al. The heterogeneity of antipsychotic response in the treatment of schizophrenia. Psychol Med. 2011;41:1291-1300.
11. Shobo M, Yamada H, Koakutsu A, et al. Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats. Life Sci. 2011;88:761-765.
12. van der Zwaal EM, Luijendijk MC, Evers SS, et al. Olanzapine affects locomotor activity and meal size in male rats. Pharmacol Biochem Behav. 2010;97:130-137.
13. Teff KL, Kim SF. Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism. Physiol Behav. 2011;104: 590-598.
14. Bai FL, Yamano M, Shiotani Y, et al. An arcuato-paraventricular and-dorsomedial hypothalamic neuropeptide YYcontaining system which lacks noradrenaline in the rat. Brain Res. 1985;331:172-175.
15. Lin S, Boey D, Herzog H. NP-and Y receptors: lessons from transgenic and knockout models. Neuropeptides. 2004;38:189-200.
16. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature. 2000;404:661-671.
17. Nguyen AD, Herzog H, Sainsbury A. Neuropeptide Yand peptide YY: important regulators of energy metabolism. Curr Opin Endocrinol Diabetes Obes. 2011;18:56-60.
18. Zhang L, Bijker MS, Herzog H. The neuropeptide Y system: pathophysiological and therapeutic implications in obesity and cancer. Pharmacol Ther. 2011;131:91-113.
19. Chee MJ, Colmers WF. Yeat? Nutrition. 2008;24:869-877.
20. Davoodi N, Kalinichev M, Korneev SA, et al. Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacology (Berl). 2009; 203:693-702.
21. Guesdon B, Denis RG, Richard D. Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance. Behav Brain Res. 2010;207:14-20.
22. Huang XF, Deng C, Zavitsanou K. Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats. Neuropeptides. 2006;40:213-219.
23. Secher A, Husum H, Holst B, et al. Risperidone treatment increases CB1 receptor binding in rat brain. Neuroendocrinology. 2010;91: 155-168.
24. Kirk SL, Cahir M, Reynolds GP. Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus. J Psychopharmacol. 2006;20:577-579.
25. Ferno J, Varela L, Skrede S, et al. Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLoS One. 2011;6:e20571.
26. Martins PJ, Haas M, Obici S. Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes. 2010;59:2418-2425.
27. Nikisch G, Baumann P, Liu T, et al. Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response. Int J Neuropsychopharmacol. 2012:15:1051-1061.
28. Zhang L, Lee NJ, Nguyen AD, et al. Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation. Diabetes Obes Metab. 2010;12:591-603.
29. Karvonen MK, Pesonen U, Koulu M, et al. Association of a leucine(7)-to-proline(7) polymorphism in the signal peptide of neuropeptide Y with high serum cholesterol and LDL cholesterol levels. Nat Med. 1998;4:1434-1437.
30. Uusitupa MI, Karvonen MK, Pesonen U, et al. Neuropeptide Y: a novel link between the neuroendocrine system and cholesterol metabolism. Ann Med. 1998;30:508-510.
31. de Leon J, Correa JC, Ruano G, et al. Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr Res. 2008;98:40-46.
32. Mattevi VS, Zembrzuski VM, Hutz MH. Association analysis of genes involved in the leptin-signaling pathway with obesity in Brazil. Int J Obes Relat Metab Disord. 2002;26:1179-1185.
33. van Rossum CT, Pijl H, Adan RA, et al. Polymorphisms in the NPY and AGRP genes and body fatness in Dutch adults. Int J Obes (Lond). 2006;30:1522-1528.
34. Yeung EH, Zhang C, Chen J, et al. Polymorphisms in the neuropeptide Y gene and the risk of obesity: findings from two prospective cohorts. J Clin Endocrinol Metab. 2011;96:E2055-E2062.
35. Nordman S, Ding B, Ostenson CG, et al. Leu7Pro polymorphism in the neuropeptide Y (NPY) gene is associated with impaired glucose tolerance and type 2 diabetes in Swedish men. Exp Clin Endocrinol Diabetes. 2005;113:282-287.
36. Pesonen U. NPY L7P polymorphism and metabolic diseases. Regul Pept. 2008;149:51-55.
37. Zhou Z, Zhu G, Hariri AR, et al. Genetic variation in human NPY expression affects stress response and emotion. Nature. 2008;452: 997-1001.
38. Itokawa M, Arai M, Kato S, et al. Association between a novel polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia in humans. Neurosci Lett. 2003;347:202-204.
39. Buckland PR, Hoogendoorn B, Guy CA, et al. A high proportion of polymorphisms in the promoters of brain expressed genes influences transcriptional activity. Biochim Biophys Acta. 2004;1690:238-249.
40. Sommer WH, Lidstrom J, Sun H, et al. Human NPY promoter variation rs16147:T 9 C as a moderator of prefrontal NPY gene expression and negative affect. Hum Mutat. 2010;31:E1594-E1608.
41. Shah SH, Freedman NJ, Zhang L, et al. Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. PLoS Genet. 2009;5:e1000318.
42. Ruano G, Goethe JW, Caley C, et al. Physiogenomic comparison of weight profiles of olanzapine-and risperidone-treated patients. Mol Psychiatry. 2007;12:474-482.
43. Tiwari AK, Zai CC, Likhodi O, et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology. 2010;35:1315-1324.
44. Tiwari AK, Rodgers JB, Sicard M, et al. Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:1484-1490.
45. Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991;19:5444.
46. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol. 2003;25:115-121.
47. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
48. Nyholt DR. A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet. 2004;74:765-769.
49. Gauderman WJ, Morrison JM. A computer program for power and sample size calculations for genetic-epidemiology studies. Available at: http://hydra.usc.edu/gxe. 2006. Accessed September 19, 2011.
50. Calle ML, Urrea V, Malats N, et al. mbmdr: An R package for exploring gene-gene interactions associated with binary or quantitative traits. Bioinformatics. 2010;26:2198-2199.
51. Mickey BJ, Zhou Z, Heitzeg MM, et al. Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry. 2011;68:158-166.
52. Fitzgerald PB, Scaffidi A, Morris MJ, et al. The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. Hum Psychopharmacol. 2003;18:551-557.
53. 2C receptor and antipsychotic-induced weight gainVmechanisms and genetics. J Psychopharmacol. 2006;20:15-18.
54. 1 receptorYlinked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA. 2007;104:3456-3459.
55. Kohno D, Sone H, Tanaka S, et al. AMP-activated protein kinase activates neuropeptide Y neurons in the hypothalamic arcuate nucleus to increase food intake in rats. Neurosci Lett. 2011;499:194-198.
56. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112:423-431.
57. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410:822-825.
58. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115:1298-1305.
59. Ravinet Trillou C, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol. 2003;284:R345-R353.
60. Ravinet Trillou C, Delgorge C, Menet C, et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 2004;28:640-648.
61. Jamshidi N, Taylor DA. Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats. Br J Pharmacol. 2001;134:1151-1154.
62. Gamber KM, Macarthur H, Westfall TC. Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology. 2005;49:646-652.